Recombinant protein · Protein replacement · developed by Novo Nordisk
Nonacog beta pegol is a recombinant coagulation factor IX that has been glycoPEGylated. It is studied in haemophilia B, a bleeding disorder caused by deficiency of factor IX.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03690336 | N/A | Haemophilia B | Enrolling by invitation | NVO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Haemophilia B
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVO page.
See NVO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVO catalysts and pipeline →